Residue analyses and exposure assessment of the Irish population to nitrofuran metabolites from different food commodities in 2009–2010

peer-reviewedAn exposure assessment to nitrofuran residues was performed for three human populations (adults, teenagers and children), based on residue analyses of foods of animal origin (liver, honey, eggs and aquaculture) covering the 2-year period 2009– 2010. The occurrence of nitrofuran metabolites in food on the Irish market was determined for the selected period using the data from Ireland’s National Food Residue Database (NFRD) and from results obtained from the analysis of retail samples (aquaculture and honey). Laboratory analyses of residues were performed by methods validated in accordance with Commission Decision 2002/657/EC regarding performance of the analytical method and interpretation of results. Semicarbazide (SEM) was the contaminant most frequently identified and its content ranged from 0.09 to 1.27 μg kg−1. SEM is currently used as a marker of nitrofuran abuse, but it may also occur from other sources. The presence of nitrofuran metabolite 3-amino-2-oxazolidinone (AOZ) was detected in two aquaculture samples (prawns) at 1.63 and 1.14 μg kg−1, but such a low number of positive cases did not present sufficient data for a full AOZ exposure assessment. Therefore, the evaluation of exposure was focused on SEM-containing food groups only. Exposure assessments were completed using a probabilistic approach that generated 10 iterations. The results of both the upper- and lower-bound exposure assessments demonstrate that SEM exposure for Irish adults, teenagers and children from selected food commodities are well below EFSA-estimated safe levels.This research was funded by the Food for Health Research Initiative (FHRI) administered by the Irish Department of Agriculture, Food and the Marine and the Health Research Board (Contract 07FHRIAFRC5

UCF Space Day Life Cycle Design (in 15 Minutes or Less)

No abstract availabl

NASA Integrated Model Centric Architecture (NIMA) Model Use and Re-Use

This whitepaper accepts the goals, needs and objectives of NASA's Integrated Model-centric Architecture (NIMA); adds experience and expertise from the Constellation program as well as NASA's architecture development efforts; and provides suggested concepts, practices and norms that nurture and enable model use and re-use across programs, projects and other complex endeavors. Key components include the ability to effectively move relevant information through a large community, process patterns that support model reuse and the identification of the necessary meta-information (ex. history, credibility, and provenance) to safely use and re-use that information. In order to successfully Use and Re-Use Models and Simulations we must define and meet key organizational and structural needs: 1. We must understand and acknowledge all the roles and players involved from the initial need identification through to the final product, as well as how they change across the lifecycle. 2. We must create the necessary structural elements to store and share NIMA-enabled information throughout the Program or Project lifecycle. 3. We must create the necessary organizational processes to stand up and execute a NIMA-enabled Program or Project throughout its lifecycle. NASA must meet all three of these needs to successfully use and re-use models. The ability to Reuse Models a key component of NIMA and the capabilities inherent in NIMA are key to accomplishing NASA's space exploration goals. 1

Playing Nice Across Time and Space

Presentation will cover elements of modeling and simulation technologies, including game technologies, as applied to maturation of new and disruptive technologies

Playing Nice Across Time Space

Presentation is a discussion on NASA Lessons Observed related to large complex system design

Modeling and Simulation: Goals, Successes and Future Challenges (How to Play Nice, Together, Across Time and Space)

No abstract availabl

Thoughts on Social, Technical and System Challenges Associated with Space Exploration Or, How to Play Nice Across Time and Space

No abstract availabl

What We Did Last Summer: Depicting DES Data to Enhance Simulation Utility and Use

At Kennedy Space Center (KSC), an important use of Discrete Event Simulation (DES) addresses ground operations .of missions to space. DES allows managers, scientists and engineers to assess the number of missions KSC can complete on a given schedule within different facilities, the effects of various configurations of resources and detect possible problems or unwanted situations. For fifteen years, DES has supported KSC efficiency, cost savings and improved safety and performance. The dense and abstract DES data, however, proves difficult to comprehend and, NASA managers realized, is subject to misinterpretation, misunderstanding and even, misuse. In summer 2008, KSC developed and implemented a NASA Exploration Systems Mission Directorate (ESMD) project based on the premise that visualization could enhance NASA's understanding and use of DES

October 9, 2006

The Breeze is the student newspaper of James Madison University in Harrisonburg, Virginia

The use of systematic reviews in the planning, design and conduct of randomised trials: a retrospective cohort of NIHR HTA funded trials

BACKGROUND: A systematic review, with or without a meta-analysis, should be undertaken to determine if the research question of interest has already been answered before a new trial begins. There has been limited research on how systematic reviews are used within the design of new trials, the aims of this study were to investigate how systematic reviews of earlier trials are used in the planning and design of new randomised trials. METHODS: Documentation from the application process for all randomised trials funded by the National Institute for Health Research Health Technology Assessment (NIHR HTA) between 2006 and 2008 were obtained. This included the: commissioning brief (if appropriate), outline application, minutes of the Board meeting in which the outline application was discussed, full application, detailed project description, referee comments, investigator response to referee comments, Board minutes on the full application and the trial protocol. Data were extracted on references to systematic reviews and how any such reviews had been used in the planning and design of the trial. RESULTS: 50 randomised trials were funded by NIHR HTA during this period and documentation was available for 48 of these. The cohort was predominately individually randomised parallel trials aiming to detect superiority between two treatments for a single primary outcome. 37 trials (77.1%) referenced a systematic review within the application and 20 of these (i.e. 41.7% of the total) used information contained in the systematic review in the design or planning of the new trial. The main areas in which systematic reviews were used were in the selection or definition of an outcome to be measured in the trial (7 of 37, 18.9%), the sample size calculation (7, 18.9%), the duration of follow up (8, 21.6%) and the approach to describing adverse events (9, 24.3%). Boards did not comment on the presence/absence or use of systematic reviews in any application. CONCLUSIONS: Systematic reviews were referenced in most funded applications but just over half of these used the review to inform the design. There is an expectation from funders that applicants will use a systematic review to justify the need for a new trial but no expectation regarding further use of a systematic review to aid planning and design of the trial. Guidelines for applicants and funders should be developed to promote the use of systematic reviews in the design and planning of randomised trials, to optimise delivery of new studies informed by the most up-to-date evidence base and to minimise waste in research